In an interview with PharmaShots, Douglas Onsi, CEO and President of Leap Therapeutics shares insights on the clinical data of DKN-01 along with its mechanism. He also highlights the company's growth, plans, goal etc.Shots:DKK1 is a secreted protein that modulates cell signaling pathways known as the Wnt signaling pathways, as well as the PI3 kinase…
